Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ProBioGen Signs Next GlymaxX® ADCC Technology Deal with TOP 10 Pharma Company

Published: Wednesday, February 20, 2013
Last Updated: Wednesday, February 20, 2013
Bookmark and Share
GlymaxX® ADCC-enhancement technology licensed by pharma company.

Another global pharma company has licensed ProBioGen’s GlymaxX® ADCC-enhancement technology.

The license covers the modification of the pharma’s antibody production platform for the generation of antibodies with enhanced potency.

The continued licensing success demonstrates the industry’s endorsement of GlymaxX®. The GlymaxX® technology is highly versatile since it can be applied to any starter or production cell line.

It allows both, the robust permanent modification of established antibody expression platforms, as well as the rapid conversion of existing antibody producer clones to produce ADCC-enhanced molecules.

The GlymaxX® technology is based on the stable expression of a heterologous enzyme in the antibody producing cells.

GlymaxX® prevents antibody fucosylation almost completely, but moreover allows the exact adjustment of any desired fucosylation level through the controlled addition of fucose into the culture medium.

The license with an option for a commercial license covers the modification of the company’s antibody production platform and the generation of multiple antibodies with enhanced ADCC potency. Financial details are not disclosed.

The technology can be licensed royalty-free, based on milestone-dependent license fees only.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ProBioGen, Eucodis Sign Agreement
Company has signed an exclusive license agreement with Eucodis Bioscience to commercialize C-LiNK, a novel antibody drug conjugation technology.
Wednesday, April 20, 2016
ProBioGen in Biosimilar Deal with Bio Farma Indonesia
Trastuzumab development and transfer for first indonesian on-site production.
Thursday, October 29, 2015
ProBioGen and Tizona Therapeutics Sign Agreement
ADCC-enhancement for innovative cancer therapy, produced via ProBioGen’s accelerated CMC development path.
Tuesday, October 06, 2015
Anti-Ebola MVA Vaccine Produced on Avian AGE1.CR® Cell Line in Clinical Trials
"Production of the first ever batch of MVA for a clinical trial using a cell line".
Wednesday, June 03, 2015
20 Years ProBioGen
Invests €20 million in mammalian manufacturing expansion.
Wednesday, September 10, 2014
ProBioGen Signs GlymaxX ADCC Enhancement Technology License Deal
A non-exclusive commercial multi-product licensing agreement with Novartis.
Tuesday, June 24, 2014
ProBioGen and Merus Sign Deal on GlymaxX® ADCC Enhancement Technology
GlymaxX® manufacturing technology improves bispecific antibody activity for solid tumor treatment.
Wednesday, March 05, 2014
ProBioGen and Emergent BioSolutions Partner
ProBioGen announces expansion of commercial licenses with Emergent BioSolutions for AGE1.CR® viral vaccine manufacturing production platform.
Tuesday, December 17, 2013
ProBioGen Upholds Strong Patent Position in Viral Vaccine Manufacturing Field
Company offers licenses and contract research services to human and animal vaccine companies.
Thursday, October 31, 2013
ProBioGen Signs Deal with TOP 10 Pharma Company for Therapeutic Antibody Platform
Another global pharma company has licensed ProBioGen’s GlymaxX® ADCC-enhancement technology.
Wednesday, February 20, 2013
Ceva and ProBioGen Signs Multi-product License Agreement
Ceva takes commercial license for ProBioGen’s AGE1.CR® cell line for viral vaccine production.
Friday, March 16, 2012
ProBioGen and Inhibrx Sign License Deal on GlymaxX® ADCC Technology
GlymaxX® ADCC technology and mammalian cell line development and manufacturing services used to advance therapeutic antibodies.
Friday, October 28, 2011
ProBioGen Signs Therapeutic Protein Process Development Contract with Virdante Pharmaceuticals
ProBioGen to contribute producer cell line development and process engineering for Virdante’s therapeutic protein.
Wednesday, April 28, 2010
Scientific News
Computational Model Finds New Protein-Protein Interactions
Researchers at University of Pittsburgh have discovered 500 new protein-protein interactions (PPIs) associated with genes linked to schizophrenia.
Experimental Drug Cancels Effect from Key Intellectual Disability Gene
A University of Wisconsin—Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse — in mice — damage from the mutation that causes the syndrome.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Bioreactors Ready for the Big Time
Bioreactors are passive filtration systems that can reduce nitrate losses from farm fields.
Analysis of Dog Genome will Provide Insight into Human Disease
An important model in studying human disease, the non-coding RNA of the canine genome is an essential starting point for evolutionary and biomedical studies – according to a new study led by The Genome Analysis Centre (TGAC).
‘Mini-Brains’ to Study Zika
Novel tool expected to speed research on brain and drug development.
Finding Factors That Protect Against Flu
A clinical trial examining the body’s response to seasonal flu suggests new approaches for evaluating the effectiveness of seasonal flu vaccines.
New Insights into Gene Regulation
Researchers have solved the three-dimensional structure of a gene repression complex that is known to play a role in cancer.
Controlling RNA in Living Cells
Modular, programmable proteins can be used to track or manipulate gene expression.
Common Class of Cancer Drugs May Not Lead to Cognitive Decline
UCLA study refutes 2015 research suggesting anthracyclines could cause memory loss, other impairments.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!